CClinicalTrials.gg
RecruitingNCT07690514Updated Jul 8, 2026

Theta Burst Transcranial Focused Ultrasound as a Novel Treatment for Cervical Dystonia

An interventional study of LIFUS - GPi Active and LIFUS - DN Active in Cervical Dystonia, sponsored by Robert Chen. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Robert Chen · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

This study is a single-blinded, randomized control study that aims to recruit 48 participants. Participants will be "randomized" into one of the study arms of the study: active stimulation to GPi, active stimulation to DN, or sham stimulation. The purpose of the study is to look into the effects of LIFUS in patients with cervical dystonia. The participation will include seven study visits, at least 24 hours apart. All study visits will take place at TWH. The first visit is a screening visit. Visits 2-6 will be on consecutive days. Visit 7 will be a week from Visit 6 or from your last day of LIFUS, whichever comes first.

Read the detailed description

Patients will be randomly assigned to one of three conditions (n =12 per condition): 1) bilateral tbLIFUS of the GPi, 2) bilateral tbLIFUS of the DN, and 3) bilateral sham tbLIFUS. Study participants will be randomized in a 1:1:1 fashion. In each group, the patients will receive tbLIFUS for five consecutive days. tbLIFUS will consist of two 120 s stimulation (one for each hemisphere, separated by 1 min). Visit 1 will consist of an anatomical MRI scan for each subject to allow accurate targeting of the GPi and DN, and for modelling the ultrasound distribution. Visit 2 will consist of baseline clinical assessments followed by pre-LIFUS rsfMRI. Immediately after, patients will receive tbLIFUS. Visits 3-5 will consist of tbLIFUS only. In Visit 6 (day 5 of stimulation), patients will receive tbLIFUS followed by rsfMRI and clinical assessments. In Visit 7, patients will undergo clinical assessments one week (+/- 3 days) after the last stimulation session in Visit 6. All patients and evaluators will be blinded to the stimulation condition. Visits 2-6 (stimulation days) will be conducted on five consecutive days. Outcome variables will be functional connectivity using rsfMRI, dystonia assessment (TWSTRS and DNMSQuest), cerebellar function assessment (Scale for the Assessment and Rating of Ataxia, SARA), head angle, tremor measurements, and phasic neck movements. SARA will be used in all conditions but will be primarily used to ensure that our protocol does not cause cerebellar dysfunction due to tbLIFUS of the DN. Tremor and phasic neck movements will be quantified with a three-axis accelerometer and neck angle will be measured using a goniometer. All clinical assessments will be video recorded and scored by two blinded movement disorders neurologists.

02

Conditions studied

  • Cervical Dystonia

Browse trials for

Keywords

  • Cervical Dystonia
03

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 18 - 90 years of age
  • Confirmed diagnosis cervical dystonia
  • 3 months since last botulinum toxin injection
  • Stable medications in the past month

Exclusion criteria

Exclusion Criteria:

  • Has neurological disorder other than dystonia (such as compressive neuropathy, limb trauma, epilepsy)
  • Cognitive deficits leading to inability to understand study purposes and risks as well as the consent information without legal trustee
  • Presence of metal implanted in body that is contraindicated in MRI
  • Pregnancy
  • Has a previous surgical intervention to treat CD such as lesioning or a DBS system in place
  • Major systemic illness or infection
04

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    LIFUS - GPi

    Bilateral thetaburst LIFUS stimulation to globus pallidus

    Device: LIFUS - GPi Active

  • Experimental
    LIFUS - DN

    Bilateral thetaburst LIFUS stimulation to dentate nucleus

    Device: LIFUS - DN Active

  • Sham comparator
    LIFUS - Sham

    Bilateral Sham LIFUS stimulation

    Device: LIFUS - Sham

Interventions

  • DeviceLIFUS - GPi Active

    Bilateral thetaburst LIFUS stimulation to the globus pallidus

  • DeviceLIFUS - DN Active

    Bilateral thetaburst LIFUS stimulation to dentate nucleus

  • DeviceLIFUS - Sham

    Bilateral sham (placebo) LIFUS stimulation

05

What researchers measure

Primary outcomes

  1. Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)

    Dystonia Assessment

    Time frame: from Visit 2 prior to stimulation to up to 2 weeks

  2. Resting State Functional MRI

    Time frame: from Visit 2 prior to stimulation to up to 1 week

  3. Dystonia non-motor symptoms questionnaire (DNMSQuest)

    Dystonia Assessment

    Time frame: from Visit 2 prior to stimulation to up to 2 weeks

06

Study locations

1 of 1 sites recruiting
  • Toronto Western Hospital
    Toronto, Ontario M5T 2S8, Canada
    • Julian Kwok · Contact · julian.kwok@uhn.ca · 416-603-5800
    • Robert Chen, MD · Principal investigator
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07690514
Lead sponsor
Robert Chen
Responsible party
Robert Chen (Clinician Scientist, University Health Network, Toronto) — Sponsor-investigator
First posted
Jul 8, 2026
Start date
Nov 18, 2024
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Jul 8, 2026

Study contacts

Jean-Francois Nankoo, PhD
Contact
jean-francois.nankoo@uhn.ca
416-603-5792
Julian Kwok
Contact
julian.kwok@uhn.ca
416-603-5800 ext. 2708
Robert Chen, MD
principal investigator · University Health Network, Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion